These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

265 related articles for article (PubMed ID: 29339439)

  • 1.
    Molenaar RJ; Radivoyevitch T; Nagata Y; Khurshed M; Przychodzen B; Makishima H; Xu M; Bleeker FE; Wilmink JW; Carraway HE; Mukherjee S; Sekeres MA; van Noorden CJF; Maciejewski JP
    Clin Cancer Res; 2018 Apr; 24(7):1705-1715. PubMed ID: 29339439
    [No Abstract]   [Full Text] [Related]  

  • 2. Targeting PARP proteins in acute leukemia: DNA damage response inhibition and therapeutic strategies.
    Padella A; Ghelli Luserna Di Rorà A; Marconi G; Ghetti M; Martinelli G; Simonetti G
    J Hematol Oncol; 2022 Jan; 15(1):10. PubMed ID: 35065680
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In vivo anti-tumor effect of PARP inhibition in IDH1/2 mutant MDS/AML resistant to targeted inhibitors of mutant IDH1/2.
    Gbyli R; Song Y; Liu W; Gao Y; Biancon G; Chandhok NS; Wang X; Fu X; Patel A; Sundaram R; Tebaldi T; Mamillapalli P; Zeidan AM; Flavell RA; Prebet T; Bindra RS; Halene S
    Leukemia; 2022 May; 36(5):1313-1323. PubMed ID: 35273342
    [TBL] [Abstract][Full Text] [Related]  

  • 4.
    Cancer Discov; 2017 Apr; 7(4):OF4. PubMed ID: 28228392
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Contemporary outcomes in IDH-mutated acute myeloid leukemia: The impact of co-occurring NPM1 mutations and venetoclax-based treatment.
    Lachowiez CA; Reville PK; Kantarjian H; Jabbour E; Borthakur G; Daver N; Issa G; Furudate K; Tanaka T; Pierce S; Tang G; Patel KP; Medeiros J; Abbas HA; Haddad F; Hammond D; Short NJ; Maiti A; Yilmaz M; Sasaki K; Takahashi K; Pemmaraju N; Konopleva M; Garcia-Manero G; Ravandi F; Kadia TM; Loghavi S; DiNardo CD
    Am J Hematol; 2022 Nov; 97(11):1443-1452. PubMed ID: 36054614
    [TBL] [Abstract][Full Text] [Related]  

  • 6. BRCA1, PARP1 and γH2AX in acute myeloid leukemia: Role as biomarkers of response to the PARP inhibitor olaparib.
    Faraoni I; Compagnone M; Lavorgna S; Angelini DF; Cencioni MT; Piras E; Panetta P; Ottone T; Dolci S; Venditti A; Graziani G; Lo-Coco F
    Biochim Biophys Acta; 2015 Mar; 1852(3):462-72. PubMed ID: 25483710
    [TBL] [Abstract][Full Text] [Related]  

  • 7. PARP inhibitor plus radiotherapy reshape the immune suppressive microenvironment and potentiate the efficacy of immune checkpoint inhibitors in tumors with IDH1 mutation.
    Hu X; Zhao M; Bai M; Xue Z; Wang F; Zhu Z; Yu J; Yue J
    Cancer Lett; 2024 Apr; 586():216676. PubMed ID: 38278469
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Type and location of isocitrate dehydrogenase mutations influence clinical characteristics and disease outcome of acute myeloid leukemia.
    Koszarska M; Bors A; Feczko A; Meggyesi N; Batai A; Csomor J; Adam E; Kozma A; Orban TI; Lovas N; Sipos A; Karaszi E; Dolgos J; Fekete S; Reichardt J; Lehoczky E; Masszi T; Tordai A; Andrikovics H
    Leuk Lymphoma; 2013 May; 54(5):1028-35. PubMed ID: 23039322
    [TBL] [Abstract][Full Text] [Related]  

  • 9. PARP goes the weasel! Emerging role of PARP inhibitors in acute leukemias.
    Fritz C; Portwood SM; Przespolewski A; Wang ES
    Blood Rev; 2021 Jan; 45():100696. PubMed ID: 32482307
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Olutasidenib: a novel mutant IDH1 inhibitor for the treatment of relapsed or refractory acute myeloid leukemia.
    Cortes JE
    Expert Rev Hematol; 2024 Jun; 17(6):211-221. PubMed ID: 38747392
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Histone deacetylase inhibitor, suberoylanilide hydroxamic acid (SAHA), enhances anti-tumor effects of the poly (ADP-ribose) polymerase (PARP) inhibitor olaparib in triple-negative breast cancer cells.
    Min A; Im SA; Kim DK; Song SH; Kim HJ; Lee KH; Kim TY; Han SW; Oh DY; Kim TY; O'Connor MJ; Bang YJ
    Breast Cancer Res; 2015 Mar; 17():33. PubMed ID: 25888415
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Oncometabolite 2-hydroxyglutarate suppresses basal protein levels of DNA polymerase beta that enhances alkylating agent and PARG inhibition induced cytotoxicity.
    Saville KM; Al-Rahahleh RQ; Siddiqui AH; Andrews ME; Roos WP; Koczor CA; Andrews JF; Hayat F; Migaud ME; Sobol RW
    DNA Repair (Amst); 2024 Aug; 140():103700. PubMed ID: 38897003
    [TBL] [Abstract][Full Text] [Related]  

  • 13. IDH2 mutations in patients with normal karyotype AML predict favorable responses to daunorubicin, cytarabine and cladribine regimen.
    Libura M; Bialopiotrowicz E; Giebel S; Wierzbowska A; Roboz GJ; Piatkowska-Jakubas B; Pawelczyk M; Gorniak P; Borg K; Wojtas M; Florek I; Matiakowska K; Jazwiec B; Solarska I; Noyszewska-Kania M; Piechna K; Zawada M; Czekalska S; Salamanczuk Z; Karabin K; Wasilewska K; Paluszewska M; Urbanowska E; Gajkowska-Kulik J; Semenczuk G; Rybka J; Wrobel T; Ejduk A; Kata D; Grosicki S; Robak T; Pluta A; Kominek A; Piwocka K; Pyziak K; Sroka-Porada A; Wrobel A; Przybylowicz A; Wojtaszewska M; Lewandowski K; Gil L; Piekarska A; Knopinska W; Bolkun L; Warzocha K; Kuliczkowski K; Sacha T; Basak G; Jedrzejczak WW; Holowiecki J; Juszczynski P; Haus O
    Sci Rep; 2021 May; 11(1):10017. PubMed ID: 33976256
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Synthetic lethal targeting of oncogenic transcription factors in acute leukemia by PARP inhibitors.
    Esposito MT; Zhao L; Fung TK; Rane JK; Wilson A; Martin N; Gil J; Leung AY; Ashworth A; So CW
    Nat Med; 2015 Dec; 21(12):1481-90. PubMed ID: 26594843
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mechanistic Dissection of PARP1 Trapping and the Impact on In Vivo Tolerability and Efficacy of PARP Inhibitors.
    Hopkins TA; Shi Y; Rodriguez LE; Solomon LR; Donawho CK; DiGiammarino EL; Panchal SC; Wilsbacher JL; Gao W; Olson AM; Stolarik DF; Osterling DJ; Johnson EF; Maag D
    Mol Cancer Res; 2015 Nov; 13(11):1465-77. PubMed ID: 26217019
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Molecular alterations of isocitrate dehydrogenase 1 and 2 (IDH1 and IDH2) metabolic genes and additional genetic mutations in newly diagnosed acute myeloid leukemia patients.
    Chotirat S; Thongnoppakhun W; Promsuwicha O; Boonthimat C; Auewarakul CU
    J Hematol Oncol; 2012 Mar; 5():5. PubMed ID: 22397365
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pretreatment d-2-hydroxyglutarate serum levels negatively impact on outcome in IDH1-mutated acute myeloid leukemia.
    Balss J; Thiede C; Bochtler T; Okun JG; Saadati M; Benner A; Pusch S; Ehninger G; Schaich M; Ho AD; von Deimling A; Krämer A; Heilig CE
    Leukemia; 2016 Apr; 30(4):782-8. PubMed ID: 26582645
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inhibition of poly(ADP-ribose) polymerase 1 protects against acute myeloid leukemia by suppressing the myeloproliferative leukemia virus oncogene.
    Wang L; Cai W; Zhang W; Chen X; Dong W; Tang D; Zhang Y; Ji C; Zhang M
    Oncotarget; 2015 Sep; 6(29):27490-504. PubMed ID: 26314963
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Poly(adenosine diphosphate ribose) polymerase inhibitors induce autophagy-mediated drug resistance in ovarian cancer cells, xenografts, and patient-derived xenograft models.
    Santiago-O'Farrill JM; Weroha SJ; Hou X; Oberg AL; Heinzen EP; Maurer MJ; Pang L; Rask P; Amaravadi RK; Becker SE; Romero I; Rubio MJ; Matias-Guiu X; Santacana M; Llombart-Cussac A; Poveda A; Lu Z; Bast RC
    Cancer; 2020 Feb; 126(4):894-907. PubMed ID: 31714594
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cannabinoids induce cell death in leukaemic cells through Parthanatos and PARP-related metabolic disruptions.
    Medrano M; Contreras M; Caballero-Velázquez T; Martínez L; Bejarano-García JA; Calderón-Ruiz R; García-Calderón CB; Rosado IV; Pérez-Simón JA
    Br J Cancer; 2024 May; 130(9):1529-1541. PubMed ID: 38461169
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.